TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01204437
Drug: Capecitabine, Nab-Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
Study: NCT01743755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, once daily for four consecutive days
Study: NCT03130244
Drug: Best Medical Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
Study: NCT02742285
Drug: Artemether + lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
Study: NCT02128230
Drug: Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 27 mg/m2 on days 1-2; MEL 5 mg/m2/d, T 200 mg/d, D 20 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 75 mg/m2/d, and E 60 mg/m2/d on days 1-4.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 2nd transplant.
Study: NCT02128230
Drug: Consolidation - CFZ-TD-PACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), adriamycin (A), cyclophosphamide (C) and etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter.~Regimen: CFZ 27 mg/m2 on days 1-2; T 200 mg/d, D 40 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 300 mg/m2/d, and E 30 mg/m2/d on days 1-4.
Study: NCT02128230
Drug: Maintenance - CFZ-R(T)-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) and lenalidomide (R) are capsules and dexamethasone (D) is a pill; all will be taken by mouth.~Regimen: For Cycles 1-12 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22; lenalidomide (R) 15 mg/d on days 1-21. For Cycles 13-24 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22. T may be substituted for R at 100 mg/day at the treating physician's discretion.
Study: NCT01343303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet/capsule every 12 hours for 21 days
Study: NCT01343303
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg capsule every 12 hours for 21 days
Study: NCT01717209
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhaled nitric oxide
Study: NCT00595556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00933530
Drug: SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
Study: NCT00933530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
Study: NCT03024086
Drug: DWJ1252
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1252 and Placebo of Gasmotin
Study: NCT03891173
Drug: L-DOS47
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOS47 lyophilized powder reconstituted and diluted for iv injection
Study: NCT01561807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02760368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules
Study: NCT01926912
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
Study: NCT03943147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00794677
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
Study: NCT04707742
Drug: Vitis Xtra Forte©
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml 0,07% cetylpyridinium chloride, one minute rinse.
Study: NCT00800137
Drug: low molecular weight heparin or unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.~Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.~Last dose given in the morning(ie. \> 24 hours)of the day prior to the procedure.~Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.~Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery.
Study: NCT02215356
Drug: Chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
Study: NCT03119714
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo bid for 14-16 days
Study: NCT02017327
Drug: Lumigan 0.01%
Normalized name: Lumigan 0.01% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
Study: NCT02017327
Drug: Lumigan 0.03% Unit Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
Study: NCT03956862
Drug: GB001
Normalized name: Glebretinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablet
Study: NCT03956862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablet
Study: NCT01718691
Drug: SyB L-0501
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 90 mg/m\^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
Study: NCT03666832
Drug: TEW-7197
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEW-7197 1cycle 14days~-intake 5days, rest 2days
Study: NCT05258474
Drug: controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
Study: NCT05258474
Drug: Immediate-release nicotinamide (SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-ascending dose (SAD)
Study: NCT05258474
Drug: Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single- and multiple-ascending dose (SAD/MAD)
Study: NCT05258474
Drug: Placebo Immediate-release nicotinamide (SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-ascending dose (SAD)
Study: NCT03961230
Drug: Jueyin granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
Study: NCT03961230
Drug: Jueyin Granules Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
Study: NCT00485667
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subects received either 300mg or 450mg
Study: NCT00485667
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00485667
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005832
Drug: R115777
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg/dose BID, PO, Days 1-21, q 28days
Study: NCT01310894
Drug: TOOKAD® Soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
Study: NCT02075463
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
Study: NCT02075463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet for GSK1278863
Study: NCT02054897
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly, administrated subcutaneously (s.c. under the skin)
Study: NCT00732277
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
Study: NCT00996268
Drug: GSK2212836
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
Study: NCT02682784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00996268
Drug: GSK2212836
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
Study: NCT01187186
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02215876
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
Study: NCT02215876
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
Study: NCT00363948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study: NCT00447577
Drug: Loteprednol etabonate and tobramycin ophthalmic suspension
Normalized name: Loteprednol Etabonate and Tobramycin Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
Study: NCT00447577
Drug: Tobramycin and dexamethasone ophthalmic suspension
Normalized name: Tobramycin and Dexamethasone Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
Study: NCT01741948
Drug: Hormonal contraceptive
Normalized name: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy.
Study: NCT03351244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 week treatment period
Study: NCT01173224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
Study: NCT01173224
Drug: DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
Study: NCT00492752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (orally) twice daily
Study: NCT01377779
Drug: Oxiplex/AP gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine application of Intercoat following hysteroscopy
Study: NCT01377779
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intrauterine application of Intercoat following hysteroscopy
Study: NCT02502500
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02502500
Drug: AKB-6548
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00867399
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm for details
Study: NCT03749252
Drug: P03277
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
Study: NCT03538327
Drug: Silybin
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
Study: NCT01339247
Drug: Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
Study: NCT01339247
Drug: Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Study: NCT01223430
Drug: Si-Ni-Tang/ Placebo of Si-Ni-Tang
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
Study: NCT00794157
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT03632733
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline cream
Study: NCT03632733
Drug: Tetracycline and Clotrimazole
Normalized name: tetracycline and nystatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cream
Study: NCT02521545
Drug: BIIB061
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT01332903
Drug: [14C] AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 120 mg oral dose administered on Day 1
Study: NCT02404259
Drug: TDF (Tenofovir)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04036890
Drug: 2% minocycline hydrochloride controlled-delivery system (MHS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
Study: NCT04036890
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is the same gel as MHS but without active ingredient minocycline hydrochloride.
Study: NCT00836056
Drug: Clindamycin 300 mg capsule
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 300 mg
Study: NCT02488564
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
Study: NCT03742258
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03742258
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03742258
Drug: Spleen Tyrosine Kinase Inhibitor TAK-659
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01516346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
Study: NCT01632995
Drug: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
Study: NCT04486950
Drug: TAK-951 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-951 placebo-matching intravenous infusion.
Study: NCT00401375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
Study: NCT04523220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration in the same manner as Osocimab.
Study: NCT02605824
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is a placebo agent.
Study: NCT00796653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Study: NCT03699176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral
Study: NCT00606203
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00081159
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.